Eagle Pharmaceuticals Inc (EGRX) : Lasalle Street Capital Management added new position in Eagle Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 7,846 shares of Eagle Pharmaceuticals Inc which is valued at $360,210 , the company said in a statement filed on Jul 19, 2016 with the SEC.Eagle Pharmaceuticals Inc makes up approximately 0.33% of Lasalle Street Capital Management’s portfolio.
Other Hedge Funds, Including , Lasalle Street Capital Management added EGRX to its portfolio by purchasing 7,846 company shares during the most recent quarter which is valued at $360,210. Eagle Pharmaceuticals Inc makes up approx 0.33% of Lasalle Street Capital Management’s portfolio. Simplex Trading sold out all of its stake in EGRX during the most recent quarter. The investment firm sold 2,351 shares of EGRX which is valued $107,934.Cutler Group Lp boosted its stake in EGRX in the latest quarter, The investment management firm added 1,547 additional shares and now holds a total of 2,849 shares of Eagle Pharmaceuticals Inc which is valued at $128,177. Eagle Pharmaceuticals Inc makes up approx 0.01% of Cutler Group Lp’s portfolio. Bnp Paribas Arbitrage Sa added EGRX to its portfolio by purchasing 357 company shares during the most recent quarter which is valued at $15,272.
Eagle Pharmaceuticals Inc opened for trading at $43.93 and hit $46.34 on the upside on Wednesday, eventually ending the session at $45.91, with a gain of 4.72% or 2.07 points. The heightened volatility saw the trading volume jump to 3,34,770 shares. Company has a market cap of $718 M.
On the company’s financial health, Eagle Pharmaceuticals Inc reported $-0.06 EPS for the quarter, beating the analyst consensus estimate by $ 0.24 according to the earnings call on May 9, 2016. Analyst had a consensus of $-0.30. The company had revenue of $29.60 million for the quarter, compared to analysts expectations of $14.26 million. The company’s revenue was down -18.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.31 EPS.
Many Wall Street Analysts have commented on Eagle Pharmaceuticals Inc. Shares were Downgraded by Mizuho on Jun 20, 2016 to ” Neutral” and Lowered the Price Target to $ 47 from a previous price target of $66 .Shares were Reiterated by RBC Capital Mkts on May 10, 2016 to “Outperform” and Lowered the Price Target to $ 78 from a previous price target of $94 .
Eagle Pharmaceuticals Inc. (Eagle Pharmaceuticals) is a specialty pharmaceutical company. The Company focused on developing and commercializing injectable products. It develops products that address the shortcomings as identified by physicians pharmacists and other stakeholders of existing commercially injectable products. Its two most advanced product candidates are EP-3101 (bendamustine RTD) an intravenous version of the chemotherapeutic agent that is marketed by Teva under the brand name Treanda and Ryanodex (dantrolene for MH) and an intravenous version of an approved treatment for malignant hyperthermia. Its products include EP-3101 EP-3102 Ryanodex EP-4104 EP-6101 EP-5101 EP-1101 and EP-2101. Teva markets its bendamustine product under the trade name Treanda.